Primer: Guangzhou Innogen Pharmaceutical (2591 HK) - Aug 2026
Guangzhou Innogen is a clinical-stage biopharmaceutical company transitioning to a commercial entity, centered on its core asset, Efsubaglutide...
98 Views
𝛼SK or SearchENTITY
Guangzhou Innogen Pharmaceutical (2591 HK)
Guangzhou Innogen Pharmaceutical (2591 HK)
36
Analysis
Health Care • China
Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The company focuses on innovative therapies for diabetes and other metabolic diseases, with its core product being Efsubaglutide Alfa (Diabegone) for type 2 diabetes. It was founded in 2014 and is headquartered in Shanghai, China.
morex